2023 CORIELL INSTITUTE FOR MEDICAL RESEARCH ANNUAL REPORT
Table of Contents
LETTER FROM DR. JEAN-PIERRE ISSA
A word from Coriell’s President & CEO
3
BIOBANKING
Recapping the year’s biobanking breakthroughs and events
5 ANNUAL REPORT 2 02 3
RESEARCH
COMMUNITY ENGAGEMENT
A year of growth and expansion for Coriell’s biomedical research
Coriell’s commitment to our community and the next generation of scientific pioneers
9
13
GIVING
FACTS & FIGURES
Recognizing the importance of our mission and demonstrating the worthiness of your support
Milestones and momentum
15
17
CORIELL INSTITUTE
LETTER FROM
DR. JEAN-PIERRE ISSA Coriell’s President & CEO
3
ANNUAL REPORT 2 02 3
“ I am immensely proud to present to you our Annual Report for 2023, celebrating the remarkable growth and achievements of the past few months. This year has been a testament to our commitment to research, and what we built this year will serve as Coriell’s foundation for many years to come.
groundbreaking research, cutting-edge technology, and a nurturing environment to attract the brightest minds in the industry—a major priority of mine as we grow the CCRC. Our biobank, long Coriell’s most storied pillar, celebrated significant achievements this year as well, as you’ll read in this report. Among them is the 50th anniversary of the National Institute of General Medical Sciences’ Human Genetic Cell Repository and a major paper in Nature from the Human Pangenome Reference Consortium, in which Coriell plays an important role. None of these accomplishments would have been possible without our remarkable team’s dedication, passion, and
The achievements over the last year predict one thing for Coriell’s future—growth. And that growth will stem from our transformative efforts in cancer research and as a worldleading biobank. Much of this growth will be enabled by the new Camden Cancer Research Center, a groundbreaking achievement for our region. This one-of-a-kind effort is made possible by our work to build a research team capable of such an effort. Our mission to drive discoveries and accelerate the development of life-saving therapies is focused and supported by this center, fostering a culture of creativity and collaboration among our fellow scientists.
resilience. To each member of the Coriell family, I extend my heartfelt gratitude for your unwavering commitment to our mission. You are the driving force behind our success, and your efforts continue to inspire us all. I also extend my most profound appreciation to our external partners, collaborators, donors, and supporters, without whom our endeavors would not be possible. Your belief in our mission allows us to push farther and plot an ambitious future for this historic organization. As we expand and become the new Coriell I know we can be, remember this growth is a testament to our unwavering commitment to transforming research and, ultimately,
To accommodate this great expansion, we will need new space. That will come soon as Coriell will be breaking ground
bettering people’s lives worldwide. I am filled with excitement and hope for what lies ahead.
on its new headquarters just down the road from our current location in the coming months. This new building is the most
J E A N - P I E R R E I S SA , M D
exciting endeavor in the Institute’s history. Coriell will soon
PRESIDENT & CHIEF EXECUTIVE OFFICER
have a new state-of-the-art headquarters tailor-made for our unique needs. This modern facility will serve as a hub for
CORIELL BOARD OF TRUSTEES
CHAIRMAN
Lou Bezich, MPP
Matthew Hewitt, PhD
Roland Schwarting, MD
Robert P. Kiep, III
Peter E. Driscoll, Esq.
Marc S. Maser, Esq.
Kenneth A. Somberg, MD, MBA
TRUSTEES
Christopher R. Gibson, Esq.
John Piccone
Antonio Tillis, PhD
John Apathy, MBA
Frank Giordano
Annette C. Reboli, MD
Edward D. Viner, MD
Arnaud Bastien, MD
Generosa Grana, MD, FACP
Miruna Sasu, PhD
CORIELL INSTITUTE
4
Biobanking
BANKING BREAKTHROUGHS
Coriell’s biobank made enormous strides and hit important milestones last year, continuing the Institute’s decades-long legacy of biobanking excellence.
5
ANNUAL REPORT 2 02 3
NIGMS HGCR 50th Anniversary
repository that would represent the
diagnosed with a wide range of
full range of genetic disorders. It was
neurological disorders, including some
also an altruistic idea because it was
of the most pressing diseases of our
The National Institute of General
designed from the start to address the
time—stroke, Parkinsonism, dystonia,
Medical Sciences’ Human Genetic Cell
research missions of many of the NIH
and many others. It now holds tens of
Repository (NIGMS HGCR) celebrated
institutes.”
thousands of biological samples and
its 50th anniversary at the Coriell
Over the last twelve months the
Institute with an in-person event
NIGMS HGCR continued to grow its
in which leaders of the collection
collection and distribute samples to
appeared with scientists who have
scientists around the world. Included
relied on or contributed to this
in the collection are more than 100
important collection through its
induced pluripotent stem cell lines
many years.
(iPSCs), which are invaluable tools
“The NINDS Human Genetics
for studying disease, as these cell
Resource Center is an incredible
types can be differentiated (targeted
resource for researchers investigating
to grow) into nearly any type of
neurological disorders as well as
cell in the body. The NIGMS HGCR
those studying human health and
management team at Coriell worked
disease more generally,” said Laura
directly with scientists, clinicians,
Scheinfeldt, PhD, the Principal
donors, and rare disease advocacy
Investigator of the collection at
groups to recruit new samples to
Coriell and Coriell’s Director of
its collection. In the last year, the
Repository Science. “The sheer
team made a special effort working
number of biospecimens in the
with the National Tay-Sachs & Allied
collection together with the
Diseases Association to assist with
associated clinical data makes this a
donor recruitment and blood draws
very special and unique resource.”
The NIGMS HGCR was founded in
at their family conference. The team
1972 collaboratively between Dr. Lewis
also promoted the repository at the
L. Coriell, the Institute’s founder, and
Global Genes RARE Patient Advocacy
leaders at NIGMS to create a reliable
Summit, the National Organization for
resource of cell lines representing
Rare Disorders (NORD) Rare Diseases
human disease for scientists seeking
and Orphan Products Breakthrough
biomaterials for their research. What
Summit, the American College
started as a paper catalog of a couple
of Medical Genetics and Genomics
dozen pages grew over 50 years to a
(ACMG) Annual Clinical Genetics
sprawling online resource indexing
Meeting, and the Association for
thousands of samples of various types.
Molecular Pathology (AMP)
Today, the Repository is one of the
Annual Meeting, and AMP Reference
world’s largest collections of cell lines
Material Forum.
data that is a crucial resource for the study of these diseases and disorders. These accomplishments were highlighted at the annual meeting of the American Society of Human Genetics.
Pangenome Project The Coriell team overseeing the NHGRI Sample Repository for Human Genetic Research, sponsored by the National Human Genome Research Institute, played a major role in important publications this year. Coriell was tapped in 2019 to join the new Human Pangenome Reference Consortium (HPRC) to assist with
and DNA representing rare human
genome sequencing and new sample
genetic diseases, as well as global
recruitment. The HPRC’s goal is
much more.
NINDS Repository 20th Anniversary
“I can’t think of many biomedical
The National Institute of Neurological
representing a diverse group of
Disorders and Stroke’s Human
people around the world as an update
Genetics Resource Center also
to the Human Genome Project of
celebrated its 20th anniversary last
the early 2000s.
human population diversity, and
resources that have lasted this long, and even fewer that have been maintained at the same institution for 50 years,” Dr. Judith Greenberg, former Deputy Director of NIGMS, said at the anniversary event. “It was not only visionary to build a
to sequence and assemble a new reference genome from hundreds of individuals (or a pangenome)
year. This collection, housed at Coriell since its creation, contains cell lines, DNA, and extensive de-identified clinical data from thousands of donors CORIELL INSTITUTE
To date, the HPRC has published several high-impact research papers, including two in the journal Nature,
6
that Matthew W. Mitchell, PhD,
biological samples from nonhuman
other commercial and/or private
Co-Principal Investigator of the
primates and this collection of
collections (both established and
NHGRI Sample Repository at Coriell,
nonhuman primate biomaterials was
newly onboarded), and offered a broad
served as a co-author on. The first
recently expanded to include 27
range of laboratory and biobanking
paper, published in October 2022,
unique species, up from 10 previously
services to the scientific community.
showcased results from cutting-edge
available. Several species have a
The biobank also continued to
assembly methods for high-quality
broad representation of sex and age.
support R&D efforts to innovate,
diploid human reference genomes.
These samples are only available to
offer additional services, and improve
The second detailed the first draft of a
academic and nonprofit institutions
processes to meet growing customer
human pangenome reference and was
and organizations.
needs, all while maintaining stringent
published in May of 2023.
In addition to successfully managing the prominent publicly available
Aging Cell Repository
repository collections at the Institute,
The NIA Aging Cell Repository,
team, in collaboration with other
sponsored by the National Institute on Aging, made available to researchers
compliance and quality management infrastructure requirements.
in the last year, Coriell’s biobanking departments including the Business Development team, supported many
How Coriell’s Biobanking Logistics Team Maintains Sample Integrity T H E C O R I E L L Institute for
materials, and he led an effort to
manages a complex and wide range of
Medical Research is among the most
develop and improve the many
tasks and responsibilities to ensure the
trusted biobanks in the world. The
scientific processes that go into
samples in our care are received and
collections in our care represent the
full-service biobanking. Our Cell
stored properly, and shipped with care
most diverse set of biosamples,
Culture Lab—as well as cell culture
to researchers.
and we set the gold standard in
labs around the world—still uses
quality worldwide.
techniques and tools developed by Dr.
Cyndi Peterson serves as one of
Coriell and his team.
the Team Leads for our Biobanking
This legacy for biobanking excellence
Logistics group. She answered the
is rooted deep in our history.
Today at Coriell, one team is
following questions about how we
Our founder, Dr. Lewis L. Coriell,
responsible for a sample’s care from
process, protect, and ship these
recognized early the need for
beginning to end—the Biobanking
invaluable samples.
standardized and reliable biological
Logistics team. This department
7
ANNUAL REPORT 2 02 3
What does the Biobanking Logistics team do at Coriell? The priority for our department boils down to one thing: sample integrity. Whether it’s compiling kit components to receive samples in a safe and compliant way or using advanced
in the interim. We work closely with
(upon request). DNA plates, cell
Customer Service to ensure proper
pellets, plasmid/protein/antibodies,
paperwork is in order for international
and biofluids are shipped frozen. We
shipments to avoid delays in customs.
prepare the shipping containers and packaging materials according to
We have many different types of samples in the collections in our care. How are each stored?
equipment to store them, the safety
regulations and place all necessary labels accordingly.
What would you like scientists ordering from Coriell to know about the Biobanking Logistics team?
of the samples is priority one. This
We store our cell lines either
includes all stages in between,
submerged in liquid nitrogen (glass
including equipment maintenance,
ampoules are stored at -196C) or in the
emergency transfers, distributing
vapor phase of liquid nitrogen (plastic
samples worldwide, and recording
cryovials stored at -150C). DNA is kept
Our team understands the importance
storage locations. We perform
in -80C freezers and specimen quality
of the samples in our care. We do
regular equipment maintenance
control samples are stored at -20C.
everything in our power to maintain
in order to keep our equipment
Cell pellets & biofluids are stored at
the equipment that houses the
running efficiently, such as freezer
-80C. While in process in the labs,
samples. We package samples for
maintenance and defrosting, incubator
samples can be stored anywhere from
shipment in ways that will keep them
filter changes, and alarm testing.
-196C in transport dewar flasks, up to
safe in transit so they are viable upon
37C in the incubators.
delivery. This allows researchers to
Our team is one of only a few at Coriell that sees the process from start to finish. We assemble and ship kits for sample collection, we receive those samples in multiple product types from the labs to freeze or store, and finally, we ship out these samples worldwide for researchers or deliver them internally for further processing. We are also responsible for keeping the samples organized and stored at the proper temperatures. Each storage device has unique nomenclature for how the samples are stored. It is our job to ensure proper data entry so those samples can be found upon request. Because we ship our samples all over the nation and across the globe, we have certifications for the proper packaging of biological samples for transport. We renew our certifications regularly and keep up with changes
We ship samples to scientists in over 80 countries across the world. How is a sample prepared and safely shipped? We ship samples at many different temperatures, including frozen (-80C).
continue their important work. We monitor the equipment the samples are stored in and respond in the event of a failure to transfer the contents as quickly and as safely as possible, minimizing temperature excursions for the samples. We carefully record data and verify the accuracy for samples we store for efficient relocation.
If a cell line is requested “live” the frozen cell line is delivered to Coriell’s Cell Culture Lab by our team for them to thaw and culture to a state where they are viable and safe to ship. The samples are then returned to our team to package and ship according to DOT/IATA regulations. When samples are requested frozen, our team retrieves the samples,
“Accuracy is a necessity on our team, and working together, we are successful each day.”
packages them according to DOT/ IATA regulations, and ships them on dry ice. We also ship DNA frozen
CORIELL INSTITUTE
8
Research
ACCELERATING DISCOVERY
It has been an unprecedented year for research at the Coriell Institute, vaulted by the launch of the groundbreaking Camden Cancer Research Center.
9
ANNUAL REPORT 2 02 3
CCRC
Executive Officer, who will serve as
The Camden Cancer Research Center
“The foundation of the CCRC offers
is a three-way collaboration between
this group long-term support in their
The Coriell Personalized Medicine
Coriell, and two of its neighbors
search for new knowledge and their
Collaborative, a longstanding and
in Camden, New Jersey: Cooper
work to translate that knowledge to
wide-ranging personalized medicine
University Health Care and the Cooper
new treatments.”
study established at Coriell in 2008,
the inaugural Director for the CCRC.
Coriell Personalized Medicine Collaborative
continued to bear fruit. Dara Kusic,
Medical School of Rowan University. These three organizations have
The Camden Cancer Research Center
PhD, a Bioinformatics Research
pledged an initial total of $30 million
will also expand the resources and
Scientist at Coriell, served as lead
to fund this center for 10 years.
capabilities of the three institutions
author on a study published in
by creating new facilities with state-
Genetics & Molecular Medicine
The organizations bring to the CCRC
of-the-art technology to support this
which bolstered the links between
individual expertise with Coriell’s
research. Among the new resources, a
one’s genetics and consumption
research and biobanking prowess,
new biobank will be formed to house
of caffeine. The paper, titled
Cooper University Health Care’s oft-
and distribute biological samples
“Genome-wide Association Study of
awarded clinical care and partnership
to scientists in the CCRC and other
Caffeine Consumption Using Coriell
with MD Anderson Cancer Center,
cancer researchers.
Personalized Medicine Collaborative Data,” detailed how this team of
and Cooper Medical School of Rowan University’s excellent medical
This new cancer center brings
scientists used a genome-wide
education and student research
together Coriell’s existing cancer
association study (GWAS) of CPMC
efforts.
research under one umbrella. The
data to locate several points on the
cancer research team had a highly
genome associated with caffeine
“The scientists in this partnership
productive year and their work—
consumption. Caffeine’s near
are uniquely positioned to launch
which detailed cancer biology,
universality makes it a ripe target
this one-of-a-kind effort. They come
improved therapy options, and more—
for further study.
from a range of backgrounds and
was published across many prestigious
expertise but share a goal: learn as
journals, including Clinical Cancer
much as possible about the complex
Research, Blood, Gastroenterology,
ways cancer develops in our body so
Genome Biology, and others. A list of
we can prevent or defeat it with new
the team’s publications can be found
tools and medicines,” said Jean-Pierre
in this report.
Issa, MD, Coriell’s President and Chief
New Faculty
Camden Opioid Research Initiative Scientists with the Camden Opioid Research Initiative, a research effort made up of the same three organizations as the CCRC, also published in the last year. Their article,
In January, Coriell added to its roster
titled “Patient Perceptions and the
of research faculty Xiaoxin Luke Chen,
Potential Utility of Pharmacogenetic
MD, PhD, a highly accomplished
Testing in Chronic Pain Management
scientist with a focus on cancers found
and Opioid Use Disorder in the
in the mouth and throat. Recent work
Camden Opioid Research Initiative,”
from Dr. Chen’s lab has focused on
demonstrated that a majority of
metabolism and cell signaling with
patients in the study are open to
regard to esophageal squamous cell
genetic testing as part of medication
carcinoma, a type of cancer that forms
management. This study was
in the lining of the esophagus.
published in Pharmaceutics.
But research at Coriell is not limited to cancer.
CORIELL INSTITUTE
10
Featured Publications Characterization of Reference Materials for CYP3A4 and CYP3A5: A Genetic Testing Reference Material Coordination Program Collaborative Project Gaedigk A, Boone EC, Turner AJ, van Schaik RHN, Chernova D, Wang WY, Broeckel U, Granfield CA, Hodge JC, Ly RC, Lynnes TC, Mitchell MW, Moyer AM, Oliva J, Kalman LV. The Journal of Molecular Diagnostics. June 2023:S1525-1578(23)00133-2. doi: 10.1016/j.jmoldx.2023.06.005. Epub ahead of print. PMID: 37354993.
Characterization of HZ0412a, a Novel Potent Humanized Anti-IL-6 Receptor Antibody that Blocks IL-6R Binding to Gp130 Han J, Liu X, Xu Y, Wang Q, Li L, Du K, Li C, Liu H, Chen Y, Huang J. Antibody Therapeutics. May 2023;6(2):119126. doi: 10.1093/abt/tbad008. PMID: 37324549; PMCID: PMC10262838.
Exploring Cell Competition for the Prevention and Therapy of Esophageal Squamous Cell Carcinoma Knapp K, Verchio V, Coburn-Flynn O, Li Y, Xiong Z, Morrison JC, Shersher DD, Spitz F, Chen X. Biochemical Pharmacology. June 2023;214:115639. doi: 10.1016/j. bcp.2023.115639. Epub ahead of print. PMID: 37290594.
Guadecitabine vs Treatment Choice In Newly Diagnosed Acute Myeloid Leukemia: A Global Phase 3 Randomized Study Fenaux P, Gobbi M, Kropf P, Issa JJ, Roboz GJ, Mayer J, Krauter J, Robak T, Kantarjian HM, Novak J, Jedrzejczak WW, Thomas X, Ojeda-Uribe M, Miyazaki Y, Min YH, Yeh SP, Brandwein JM, GerchevaKyuchukova LT, Demeter J, Griffiths EA, Yee KWL, Döhner K, Hao Y, Keer HN, Azab M, Döhner H. Blood Advances. June 2023 5:bloodadvances.2023010179. doi: 10.1182/ bloodadvances.2023010179. Epub ahead of print. PMID: 37276510.
A Draft Human Pangenome Reference Liao WW, Asri M, Ebler J, Doerr D, Haukness M, Hickey G, Lu S, Lucas JK, Monlong J, Abel HJ, Buonaiuto S, Chang XH, Cheng H, Chu J, Colonna V,
11
Eizenga JM, Feng X, Fischer C, Fulton RS, Garg S, Groza C, Guarracino A, Harvey WT, Heumos S, Howe K, Jain M, Lu TY, Markello C, Martin FJ, Mitchell MW, Munson KM, Mwaniki MN, Novak AM, Olsen HE, Pesout T, Porubsky D, Prins P, Sibbesen JA, Sirén J, Tomlinson C, Villani F, Vollger MR, Antonacci-Fulton LL, Baid G, Baker CA, Belyaeva A, Billis K, Carroll A, Chang PC, Cody S, Cook DE, Cook-Deegan RM, Cornejo OE, Diekhans M, Ebert P, Fairley S, Fedrigo O, Felsenfeld AL, Formenti G, Frankish A, Gao Y, Garrison NA, Giron CG, Green RE, Haggerty L, Hoekzema K, Hourlier T, Ji HP, Kenny EE, Koenig BA, Kolesnikov A, Korbel JO, Kordosky J, Koren S, Lee H, Lewis AP, Magalhães H, Marco-Sola S, Marijon P, McCartney A, McDaniel J, Mountcastle J, Nattestad M, Nurk S, Olson ND, Popejoy AB, Puiu D, Rautiainen M, Regier AA, Rhie A, Sacco S, Sanders AD, Schneider VA, Schultz BI, Shafin K, Smith MW, Sofia HJ, Abou Tayoun AN, Thibaud-Nissen F, Tricomi FF, Wagner J, Walenz B, Wood JMD, Zimin AV, Bourque G, Chaisson MJP, Flicek P, Phillippy AM, Zook JM, Eichler EE, Haussler D, Wang T, Jarvis ED, Miga KH, Garrison E, Marschall T, Hall IM, Li H, Paten B. Nature. May 2023;617(7960):312-324. doi: 10.1038/s41586-023-05896-x. Epub 2023 May 10. PMID: 37165242; PMCID: PMC10172123.
Promoter-Independent Synthesis Of Chemically Modified RNA By Human DNA Polymerase θ Variants Tredinnick T, Kent T, Minakhin L, Li Z, Madzo J, Chen XS, Pomerantz RT. RNA. August 2023;29(8):1288-1300. doi: 10.1261/rna.079396.122. Epub 2023 Apr 27. PMID: 37105714; PMCID: PMC10351887.
A Fast Machine- Learning-Guided Primer Design Pipeline For Selective Whole Genome Amplification Dwivedi-Yu JA, Oppler ZJ, Mitchell MW, Song YS, Brisson D. PLoS Computational Biololgy. April 2023;19(4):e1010137. doi: 10.1371/journal. pcbi.1010137. PMID: 37068103; PMCID: PMC10138271.
Abl1 Kinase as a Tumor Suppressor In Aml1-Eto and Nup98-Pmx1 Leukemias Golovine K, Abalakov G, Lian Z, Chatla S, Karami A, Chitrala KN, Madzo J,
ANNUAL REPORT 2 02 3
Nieborowska-Skorska M, Huang J, Skorski T. Blood Cancer Journal. March 2023;13(1):42. doi: 10.1038/s41408-02300810-0. PMID: 36959186; PMCID: PMC10036529.
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy Jang HJ, Hostetter G, Macfarlane AW, Madaj Z, Ross EA, Hinoue T, Kulchycki JR, Burgos RS, Tafseer M, Alpaugh RK, Schwebel CL, Kokate R, Geynisman DM, Zibelman MR, Ghatalia P, Nichols PW, Chung W, Madzo J, Hahn NM, Quinn DI, Issa JJ, Topper MJ, Baylin SB, Shen H, Campbell KS, Jones PA, Plimack ER. Clinical Cancer Research. June 2023 1;29(11):2052-2065. doi: 10.1158/1078-0432. CCR-22-3642. PMID: 36928921; PMCID: PMC10233355.
DNA Methylation Entropy as a Measure of Stem Cell Replication and Aging Vaidya H, Jeong HS, Keith K, Maegawa S, Calendo G, Madzo J, Jelinek J, Issa JJ. Genome Biol. 2023 Feb 16;24(1):27. doi: 10.1186/s13059-023-02866-4. Genome Biology. February 2023;24(1):104. PMID: 36797759; PMCID: PMC9933260.
TET1 and TDG Suppress Inflammatory Response in Intestinal Tumorigenesis: Implications for Colorectal Tumors With the CpG Island Methylator Phenotype Tricarico R, Madzo J, Scher G, Cohen M, Jelinek J, Maegawa S, Nagarathinam R, Scher C, Chang WC, Nicolas E, Slifker M, Zhou Y, Devarajan K, Cai KQ, Kwok T, Nakajima P, Xu J, Mancuso P, Doneddu V, Bagella L, Williams R, Balachandran S, Maskalenko N, Campbell K, Ma X, Cañadas I, Viana-Errasti J, Moreno V, Valle L, Grivennikov S, Peshkova I, Kurilenko N, Mazitova A, Koltsova E, Lee H, Walsh M, Duttweiler R, Whetstine JR, Yen TJ, Issa JP, Bellacosa A. Gastroenterology. May 2023;164(6):921936.e1. doi: 10.1053/j.gastro.2023.01.039. Epub 2023 Feb 8. PMID: 36764492.
Hypomethylation In Mtnr1b: A Novel Epigenetic Marker For Atherosclerosis Profiling Using Stenosis Radiophenotype And Blood Inflammatory Cells
Kim JY, Jelinek J, Lee YH, Kim DH, Kang K, Ryu SH, Moon HR, Cho K, Rha SH, Cha JK, Issa JJ, Kim J. Clinical Epigenetics. January 2023;15(1):11. doi: 10.1186/s13148-023-01423-x. PMID: 36658621; PMCID: PMC9854223.
Novel Treatment Strategy of Targeting Epigenetic Dysregulation in Pancreatic Neuroendocrine Tumors Zhu C, Sandilos G, Williamson J, Emery R, Platoff R, Joneja U, Acharya NK, Lin A, Badach J, Zilberman B, Madzo J, Jelinek J, Zhang P, Hong YK. Surgery. April 2023;173(4):1045-1051. doi: 10.1016/j.surg.2022.12.008. Epub 2023 Jan 13. PMID: 36642656. 14:
DNA Polymerase θ Protects Leukemia Cells from Metabolically Induced DNA Damage Vekariya U, Toma M, NieborowskaSkorska M, Le BV, Caron MC, Kukuyan AM, Sullivan-Reed K, PodszywalowBartnicka P, Chitrala KN, Atkins J, Drzewiecka M, Feng W, Chan J, Chatla S, Golovine K, Jelinek J, Sliwinski T, Ghosh J, Matlawska-Wasowska K, Chandramouly G, Nejati R, Wasik M, Sykes SM, Piwocka K, Hadzijusufovic E, Valent P, Pomerantz RT, Morton G, Childers W, Zhao H, Paietta EM, Levine RL, Tallman MS, Fernandez HF, Litzow MR, Gupta GP, Masson JY, Skorski T. Blood. May 2023;141(19):2372-2389. doi: 10.1182/blood.2022018428. PMID: 36580665; PMCID: PMC10273171.
Non-pathogenic Microbiota Accelerate Age-related CpG Island Methylation in Colonic Mucosa Sun A, Park P, Cole L, Vaidya H, Maegawa S, Keith K, Calendo G, Madzo J, Jelinek J, Jobin C, Issa JJ. Epigenetics. December 2023 Dec;18(1):2160568. doi: 10.1080/15592294.2022.2160568. Epub 2022 Dec 26. PMID: 36572998; PMCID: PMC9980687.
Semi-automated Assembly of Highquality Diploid Human Reference Genomes Jarvis ED, Formenti G, Rhie A, Guarracino A, Yang C, Wood J, Tracey A, ThibaudNissen F, Vollger MR, Porubsky D, Cheng H, Asri M, Logsdon GA, Carnevali P,
Chaisson MJP, Chin CS, Cody S, Collins J, Ebert P, Escalona M, Fedrigo O, Fulton RS, Fulton LL, Garg S, Gerton JL, Ghurye J, Granat A, Green RE, Harvey W, Hasenfeld P, Hastie A, Haukness M, Jaeger EB, Jain M, Kirsche M, Kolmogorov M, Korbel JO, Koren S, Korlach J, Lee J, Li D, Lindsay T, Lucas J, Luo F, Marschall T, Mitchell MW, McDaniel J, Nie F, Olsen HE, Olson ND, Pesout T, Potapova T, Puiu D, Regier A, Ruan J, Salzberg SL, Sanders AD, Schatz MC, Schmitt A, Schneider VA, Selvaraj S, Shafin K, Shumate A, Stitziel NO, Stober C, Torrance J, Wagner J, Wang J, Wenger A, Xiao C, Zimin AV, Zhang G, Wang T, Li H, Garrison E, Haussler D, Hall I, Zook JM, Eichler EE, Phillippy AM, Paten B, Howe K, Miga KH; Human Pangenome Reference Consortium. Nature. November 2022;611(7936):519-531. doi: 10.1038/s41586-022-05325-5. Epub 2022 Oct 19. PMID: 36261518; PMCID: PMC9668749.
Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine O’Connell CL, Baer MR, Ørskov AD, Saini SK, Duong VH, Kropf P, Hansen JW, Tsao-Wei D, Jang HS, Emadi A, Holmberg-Thyden S, Cowland J, Brinker BT, Horwood K, Burgos R, Hostetter G, Youngblood BA, Hadrup SR, Issa JP, Jones P, Baylin SB, Siddiqi I, Grønbaek K. Clinical Cancer Research. December 2022;28(24):5306-5316. doi: 10.1158/10780432.CCR-22-1810. PMID: 36222848; PMCID: PMC9772102.
Epigenome-Wide Study Identifies Epigenetic Outliers in Normal Mucosa of Patients with Colorectal Cancer
O, Smith G, Morales-Scheihing D, Buono RJ, Ferraro TN, Haroz R, Salzman M, Baston K, Bodofsky E, Sabia M, Resch A, Scheinfeldt LB. Pharmaceutics. September 2022;14(9):1863. doi: 10.3390/ pharmaceutics14091863. PMID: 36145611; PMCID: PMC9505214.
Transcriptional Responses to Injury of Regenerative Lung Alveolar Epithelium Ali M, LaCanna R, Lian Z, Huang J, Tan Y, Shao W, Yu X, Tian Y. iScience. August 2022;25(8):104843. doi: 10.1016/j.isci.2022.104843. PMID: 35996586; PMCID: PMC9391595.
Characterization of Reference Materials for TPMT and NUDT15: A GeT-RM Collaborative Project Pratt VM, Wang WY, Boone EC, Broeckel U, Cody N, Edelmann L, Gaedigk A, Lynnes TC, Medeiros EB, Moyer AM, Mitchell MW, Scott SA, Starostik P, Turner A, Kalman LV. The Journal of Molecular Diagnostics. October 2022;24(10):1079-1088. doi: 10.1016/j.jmoldx.2022.06.008. Epub 2022 Aug 2. PMID: 35931342; PMCID: PMC9554816.
Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells Pandey S, Djibo R, Darracq A, Calendo G, Zhang H, Henry RA, Andrews AJ, Baylin SB, Madzo J, Najmanovich R, Issa JJ, Raynal NJ. Cancers (Basel). July 2022;14(14):3340. doi: 10.3390/cancers14143340. PMID: 35884401; PMCID: PMC9324262.
Ghosh J, Schultz BM, Chan J, Wultsch C, Singh R, Shureiqi I, Chow S, Doymaz A, Varriano S, Driscoll M, Muse J, Kleiman FE, Krampis K, Issa JJ, Sapienza C.
Genome-wide Association Study of Caffeine Consumption Using Coriell Personalized Medicine Collaborative Data
Cancer Prevention Research (Phila). November 2022;15(11):755-766. doi: 10.1158/1940-6207.CAPR-22-0258. PMID: 36219239; PMCID: PMC9623234.
Kusic D, Zajic S, Gharani N, Gordon E, Schmidlen T, Zhang P, Gerry N, Scheinfeldt L.
Patient Perceptions and Potential Utility of Pharmacogenetic Testing in Chronic Pain Management and Opioid Use Disorder in the Camden Opioid Research Initiative Kusic D, Heil J, Zajic S, Brangan A, Dairo
CORIELL INSTITUTE
Genetics and Molecular Medicine. May 2023; 5(1): 1-10.
Community Engagement
SCIENCE IN ACTION
As scientists, we at Coriell know that our work is never finished. Each answered hypothesis begets new questions and new paths for further study.
13
ANNUAL REPORT 2 02 3
The Coriell Science Fair and Internship Program At Coriell, we acknowledge our shared responsibility to educate and train the next generation of scientists, those in school now with a passion for uncovering the fundamental truths of our world. Answering that responsibility, Coriell hosts each year the Coriell Institute Science Fair, open to young scientists across the Institute’s region in South Jersey. This year’s fair, held in March, was the 42nd such event and brought more than 100 students to Camden County College in Blackwood, New Jersey to show off their scientific curiosity and prowess. The categories for projects range from behavioral science to mathematics, engineering, physics, and more.
Winners from this year’s fair explored topics such as examining the correlation between sleep duration and students’ anxiety levels and school performance and the effects of food preservatives on the microbiome. These winners were eligible to move
A significant change to the Summer
on to the regional fair, the Delaware
Experience this year is that the
Valley Science Fair, and more than
students had the opportunity to pick a
two dozen students that competed in
focus for their time at Coriell. Students
Coriell’s fair won awards there.
could choose from working in Coriell’s Production Laboratories, with its
We also train student scientists
Research & Development team,
right at our facility in Camden, New
or in Project Management, which
Jersey, through the Coriell Summer
administers the biobanking collections
Experience. This is the second year
held at the Institute. The students also
back for the students since the start
had an opportunity to work in Coriell’s
of the pandemic, during which the
research labs.
program was temporarily replaced by the virtual Bioinformatics Research Experience.
CORIELL INSTITUTE
14
Giving 15
As you’ve read in this report, Coriell continues to make enormous strides, year after year. We’ve built a center for novel cancer research, celebrated decades-long scientific collaborations foundational to genetic research, worked with scientists around the nation on the new human pangenome—a genome that better represents every person on our planet, began planning a stateof-the-art new facility with space to grow, and helped young scientists find their passions through our science fair and internship program. Not bad for
ANNUAL REPORT 2 02 3
a biomedical research organization celebrating its 70th year. We can do all of this because of the strong support we receive from those who believe in our mission and trust our work: agencies in the National Institutes of Health, fellow academic research institutions, and private disease groups. We also receive funding from local leaders who believe in our work. And we rely on support from members of the public who share our vision for preventing and curing disease. If you would like to further support this mission, please contact us at giving@coriell.org.
OUR LEG ACY As you’ve read in this report, Coriell continues to make enormous strides, year after year GIVING@CORIELL.ORG
CORIELL INSTITUTE
16
Facts 2022
&
2023
Figures
110+ EMPLOYEES
54/46
PERCENTAGE OF WOMEN TO MEN IN SCIENTIFIC ROLES
61
NUMBER OF SCIENTISTS
194
BILLION
CELLS THAT WE’VE CULTURED IN-HOUSE
2,450 SCIENTISTS SERVED
9,027
DISEASES REPRESENTED IN OUR COLLECTION
AND SHIPPED
224
NEW DISEASES ADDED TO OUR COLLECTION
23
RESEARCH PUBLICATIONS THIS YEAR
89 COUNTRIES WE’VE SHIPPED TO
A Legacy of Innovation. A Future of Possibility. SINCE 1 9 5 3
403 Haddon Avenue, Camden, NJ 08103, USA coriell.org